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Abstract
Background: Autophagy is characterized by the sequestration of cytoplasm and organelles into multimembrane 
vesicles and subsequent degradation by the cell's lysosomal system. It is linked to many physiological functions in 
human cells including stress response, protein degradation, organelle turnover, caspase-independent cell death and 
tumor suppression. Malignant transformation is frequently associated with deregulation of autophagy and several 
tumor suppressors can modulate autophagic processes. The tumor suppressor p53 can induce autophagy after 
metabolic or genotoxic stress through transcriptionally-dependent and -independent mechanisms. In this study we 
expand on the former mechanism by functionally characterizing a p53 family target gene, ISG20L1 under conditions of 
genotoxic stress.
Results: We identified a p53 target gene, ISG20L1, and show that transcription of the gene can be regulated by all 
three p53 family members (p53, p63, and p73). We generated an antibody to ISG20L1 and found that it localizes to the 
nucleolar and perinucleolar regions of the nucleus and its protein levels increase in a p53- and p73-dependent manner 
after various forms of genotoxic stress. When ectopically expressed in epithelial cancer-derived cell lines, ISG20L1 
expression decreased clonogenic survival without a concomitant elevation in apoptosis and this effect was partially 
rescued in cells that were ATG5 deficient. Knockdown of ISG20L1 did not alter 5-FU induced apoptosis as assessed by 
PARP and caspase-3 cleavage, sub-G1 content, and DNA laddering. Thus, we investigated the role of ISG20L1 in 
autophagy, a process commonly associated with type II cell death, and found that ISG20L1 knockdown decreased 
levels of autophagic vacuoles and LC3-II after genotoxic stress as assessed by electron microscopy, biochemical, and 
immunohistochemical measurements of LC3-II.
Conclusions: Our identification of ISG20L1 as a p53 family target and discovery that modulation of this target can 
regulate autophagic processes further strengthens the connection between p53 signaling and autophagy. Given the 
keen interest in targeting autophagy as an anticancer therapeutic approach in tumor cells that are defective in 
apoptosis, investigation of genes and signaling pathways involved in cell death associated with autophagy is critical.
Background
Recently, several studies have shown that p53 can regu-
late autophagy in both a transcriptionally-dependent and
-independent manner [1]. Autophagy is commonly stud-
ied as a mechanism to maintain metabolic homeostasis in
cells undergoing starvation [2]. During starvation, cells
form double membrane autophagosomes that engulf cel-
lular contents for degradation and these vesicles then
recycle the basic metabolic components for consumption
[3]. Although originally thought to be primarily induced
under conditions of starvation to promote cell survival,
autophagy also occurs after various forms of genotoxic
stress and plays a role in cell death [4-7]. The role of p53
in DNA damage-induced autophagy is only now being
discerned as new reports show a dual role for p53 in the
process of autophagy (reviewed in [8,9]). Basal levels of
cytoplasmic p53 repress autophagy, a process that
increases after the removal or inhibition of p53 [10]. Fur-
thermore, p53 stimulates autophagy through transactiva-
tion of target genes such as Sestrins, TSC2, and DRAM
(damage-regulated autophagy modulator) (reviewed in
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Page 2 of 14[11]). Under conditions of genotoxic stress such as ioniz-
ing radiation and camptothecin treatment, p53 has been
shown to downregulate mTOR, which lies upstream of
ATG-mediated autophagy, through transcriptional regu-
lation of Sestrins1 and Sestrin2 that activate AMPK
[12,13]. Upregulated by various stress signals including
DNA damage, DRAM is a transcriptional target of p53
that is lysosomal in location and required for p53-
induced autophagy, although the direct mechanism by
which DRAM regulates autophagy is currently unknown
[14].
p63 and p73 are two p53 homologs that share similar
structure and have both unique and coordinate roles dur-
ing development and tumorigenesis [15]. The signaling
upstream of each p53 family member is dependent on
cellular context and various regulatory mechanisms
[reviewed in [16]]. Recently, work from our laboratory
has shown that in addition to the interplay of mTOR and
p53, inhibition of mTOR activates p73 and results in p73-
dependent modulation of genes involved in metabolism
and autophagy [16,17]. Though p73 also transcriptionally
regulates the p53 target gene DRAM, p73-dependent
autophagy does not require DRAM [18].
We have identified numerous, novel candidate p53 tar-
get genes by overlaying genes shown to be upregulated
after ectopic expression of p53 [19] with genomic loci
containing p53 binding sites identified using a ChIP-
based yeast one-hybrid screen [20]. Of interest was the
discovery of ISG20L1, a gene that was named due to its
significant similarity with ISG20L2, a nucleolar protein
shown to function in the processing of the 5.8S rRNA
[21]. To determine the role that ISG20L1 plays in p53
family signaling, we generated an ISG20L1-specific anti-
body, analyzed ISG20L1 regulation by all three members




The human ISG20L1 gene is 3.1 kb and evolutionarily
conserved with 72% identity to M. musculus. We gener-
ated a rabbit polyclonal antibody to the human ISG20L1
protein (UniProt Q8WTP8) using a 15 amino acid
sequence (HGSRGGAREAQDRRN) located at the C-ter-
minus of the protein outside of the exonuclease III
domain; database searching confirmed that 100% of these
residues are unique to ISG20L1. We performed Western
analyses in conjunction with gene overexpression and
knockdown assays, to determine that our newly devel-
oped antibody could specifically identify a protein of the
predicted molecular weight (~37 kD). For overexpression
analyses, protein lysates were prepared from H1299 cells
engineered to ectopically express FLAG-tagged human
ISG20L1. RNA knockdown experiments were performed
in H460 cells by reverse transfecting siRNAs directed
against ISG20L1 and subsequently treating with ionizing
radiation to upregulate endogenous ISG20L1 protein lev-
els (Figure 1a). The antibody we produced had specificity
for ISG20L1, the levels of which were significantly
reduced after siRNA knockdown or enhanced with ecto-
pic expression of ISG20L1, respectively (Figure 1a). These
results are the first demonstration of detection and regu-
lation of endogenous ISG20L1 protein.
Having confirmed antibody specificity, we analyzed the
cellular localization of ISG20L1 in H1299 cells ectopically
expressing a FLAG-tagged ISG20L1. Immunofluores-
cence analyses showed nuclear localization of ectopically
expressed ISG20L1, similar to the staining pattern seen
using a FLAG antibody (Figure 1b). Merging nuclear
DAPI staining with ISG20L1-specific staining, showed
ISG20L1 localizes to a region of the nucleus having
decreased density identified as the nucleolus and higher
magnification analyses confirm increased intensity at
perinucleolar regions (Figure 1b). Although detectable by
Western, we were unable to identify endogenous
ISG20L1 using immunofluorescence.
p53 Family Regulation of ISG20L1
To analyze p53 regulation of ISG20L1 we used primary
cultures of normal human keratinocytes (NHEKs), a
model system with intact p53 signaling [19,22]. NHEKs
were infected with control shRNA or shRNA targeting
p53 and exposed for 6 h to cisplatin to elevate p53 activ-
ity. Western analysis showed that both p53 and ISG20L1
protein levels were elevated after cisplatin treatment and
this increase was primarily p53-dependent as the shRNA
targeting p53 significantly decreased the cisplatin-
induced elevation in p53 and ISG20L1 protein levels (Fig-
ure 1c). We hypothesized that residual ISG20L1 expres-
sion was due to cisplatin-mediated elevation of TAp73
activity or protein as previously shown [23-26]. However,
p73 protein is difficult to detect in primary cultures of
normal human keratinocytes, likely due to the low level of
expression in normal cells [19].
Given the residual expression of ISG20L1 in p53-
depleted keratinocytes (Figure 1c) and the overlapping
binding and activity of p53 family members at many regu-
latory regions in the genome, we hypothesized that
ISG20L1 is also regulated by p63 and p73. To test this
hypothesis, we transfected 293FT cells with plasmids
encoding the transcriptionally active isoforms of the p53
family (p53, TAp73β, and TAp63γ) as well as the tran-
scriptional repressor ΔNp63α. These cells express low
levels of TAp73, non-detectable p63, and wild-type p53
that is stabilized and inactivated by association with E1A
and large T antigen (see pCEP4 control lane of Figure 2b).
Twenty-four h after transfection, we isolated RNA and
protein and analyzed ISG20L1 by qRT- PCR and West-
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mately 2-fold or more by p53, TAp73β, and TAp63γ while
ΔNp63α expression decreased levels of ISG20L1 as seen
at both the mRNA and protein level (Figure 2a and 2b).
Noting the elevation of ISG20L1 after TAp73 expres-
sion, we analyzed the ability of endogenous TAp73 to reg-
ulate ISG20L1 using the Rh30 rhabdomyosarcoma cell
line. Rh30 cells do not express p63 and contain mutant
p53, thereby allowing us to investigate the endogenous
regulation of ISG20L1 solely by p73. We treated cells with
paclitaxel or cisplatin, two agents known to increase p73
activity [27,28], and observed an elevation in TAp73 pro-
tein levels that were accompanied by an increase in
ISG20L1 expression (Figure 2c). Elevation of ISG20L1
was TAp73-dependent as shRNA depletion of TAp73
eliminated ISG20L1 expression after treatment (Figure
2c). To verify p73-dependent regulation was not cell-type
or damage specific, we infected MDA-MB-231, cells that
are also lacking p63 and mutant for p53, with a shRNA
lentivirus targeting p73 and treated with rapamycin, an
agent known to elevate p73 activity in this cell line [29].
Rapamycin is an inhibitor of the TOR pathway that regu-
lates cell growth and cell cycle progression based on
nutrient-dependent signaling and thus rapamycin has
similar effects as nutrient starvation [30]. ISG20L1 RNA
levels were decreased ~50% by RNAi knockdown of p73,
and rapamycin treatment resulted in a greater than 2-fold
induction in ISG20L1 expression that was abrogated with
p73 knockdown (Figure 2d). Thus, ISG20L1 can be mod-
ulated by various forms of cell stress (genotoxic and met-
abolic), and in the absence of p53 its expression is
dependent on other p53 family members.
Next we explored the ability of the p53 family members
to bind the ISG20L1 promoter region. Previous findings
Figure 1 ISG20L1 antibody production and protein analysis. (a) Western analyses demonstrated the polyclonal antibody generated was able to 
detect endogenous ISG20L1. H460 cells were reverse transfected with Dharmacon siRNA control (Con) or Dharmacon ISG20L1 Ontarget Plus pool and 
grown for 72 h, at which point the cultures were treated with 8 Gy ionizing radiation and harvested 24 h after treatment (left panel). Ectopic expression 
of a FLAG-ISG20L1 detected by our ISG20L1 antibody serves as further positive control. Asterisks mark nonspecific bands and the arrow indicates 
ISG20L1. Western is representative of three independent experiments. (b) ISG20L1 is localized to the nucleolus and perinucleolar region. RKO cells 
were transfected with either empty vector (Vector Control) or FLAG-ISG20L1 and immunofluorescence analysis was performed 24 h later using a FLAG 
antibody or the ISG20L1 antibody and the nuclei co-stained with DAPI. Views of individual and merged stainings are shown. Insets are further magni-
fication of individual cells to highlight the perinucleolar staining of ISG20L1. Immunofluorescence was performed on four independent transfections 
using ISG20L1 and FLAG antibodies. (c) p53-dependent regulation of ISG20L1 is shown by Western analysis. NHEK cells were infected with shRNA 
lentiviral constructs expressing either shRNA to p53 or a scrambled shRNA (Con) and then treated with cisplatin (5 μg/mL) for 6 h. Protein lysates were 
prepared and analyzed for p53, ISG20L1, and actin. The Western blot is representative of three independent experiments.
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scription factor binding domains, but p53 and p63 have
different affinities due to slight differences in consensus
site sequence composition and co-factor binding sites
present in the promoter regions of regulated genes [31-
34]. The p53 binding site discovered by our previous
ChIP-based screen, CCACATGCCC-0-
GGGCAAGCCC, was located approximately 450 bp
upstream of the ISG20L1 transcriptional start site and
matches the p53 canonical binding site at 18 of 20 base
pairs, with no spacer in the palindrome [20]. To deter-
mine if p53 and p63 bind and regulate ISG20L1 at the
same promoter region, we used human mammary epithe-
lial cells (HMECs) that express p53 and p63 at levels suffi-
cient for chromatin analyses [32]. HMECs were
chemically crosslinked under control and cisplatin-
Figure 2 p53 family regulates expression of ISG20L1. (a) 293FT cells were transfected with vector control (pCEP4) or the indicated p53 family 
members for 24 h and then analyzed by qRT-PCR for ISG20L1. Results represent 3 independent experiments and error bars show standard error. (b) 
Experiment was performed as in (a) and Western analysis performed. Results are representative of 3 independent experiments. *The p63 antibody 
used cross-reacts with p73 due to sequence similarity in the region containing the epitope recognized by the antibody [65]. (c) p73 regulates ISG20L1, 
seen in Rh30 cells treated with paclitaxel (5 nM) and cisplatin (5 μg/mL) for times indicated. Right panel, Rh30 cells were infected with a pSico vector 
that expresses control virus (Con) or shRNA targeting all isoforms of p73. Results are representative of 3 independent experiments. (d) MDA-MB-231 
cells were infected as above. Forty-eight h later, cells were treated with rapamycin (40 nM) and RNA harvested for real-time analyses 24 h after treat-
ment. Results represent 3 independent experiments and error bars show standard error. (e) Antibodies specific to p53, p53-Ser15 (S15), p63, and Bax 
(negative control) were used for ChIP analysis of the ISG20L1 promoter under control and cisplatin-treated (24 h, 10 μg/mL) conditions in HMECs. The 
p53 binding site in the p21 promoter and a region containing no p53 binding sites in the GAPDH promoter serve as positive and negative controls, 
respectively. Experiment is representative of duplicate independent templates. (f) ChIP analysis of p73 binding to the ISG20L1 promoter in Rh30 cells 
treated with rapamycin (40 nM) for 24 h.
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signaling axis [27,35]. Chromatin was prepared and
immunoprecipitated with antibodies to p53, p53-Ser15,
p63, and a negative control antibody against a non-DNA
binding protein (Bax). Primers were used to amplify the
region of the ISG20L1 gene previously reported to con-
tain the p53 binding site [20]. Chromatin immunoprecip-
itation analysis (ChIP) showed increased binding of p53
and p53-Ser15 after cisplatin treatment, and p63 bound
the promoter region of ISG20L1 under both control and
cisplatin treated conditions (Figure 2e). These data indi-
cate that both family members cooperate to regulate
ISG20L1 expression.
Given that HMECs do not express levels of p73 suffi-
cient for chromatin analysis we performed p73 ChIP in
the Rh30 cells to assess p73 binding levels at the ISG20L1
promoter in response to rapamycin treatment. After
rapamycin treatment, p73 binding at the p53 consensus
binding site in the ISG20L1 promoter increased ~15-fold
as compared to a vehicle only-treated control (Figure 2f).
Collectively, these data show that all three p53 family
members can bind to the promoter region of ISG20L1
and regulate its gene expression.
ISG20L1 and Cell Death
Shortly after our discovery of ISG20L1 as a p53 target
[20], ISG20L1 was reported to have exonuclease function
in vitro [36] prompting us to determine if it played a role
in DNA laddering during the execution phase of apopto-
sis. Using siRNA knockdown, we decreased ISG20L1 lev-
els in RKO cells and treated with 5-flourouracil (5-FU) to
induce apoptosis. Neither knockdown of ISG20L1 nor 5-
FU treatment after knockdown affected the onset or
extent of apoptosis as measured by analyses of PARP and
caspase-3 cleavage, sub-G1 content quantified by flow
cytometry, and DNA laddering (Figure 3a and 3b). These
data suggest that ISG20L1 does not play a role in the exe-
cution phase of apoptosis.
To determine if ISG20L1 plays a role in genotoxic
stress-induced autophagy we analyzed the effect of
ISG20L1 modulation (ectopic expression or knockdown)
in RKO cells after etoposide, a treatment that induces
autophagy. During autophagy an ubiquitin-like signaling
cascade is initiated that results in cleavage of a protein
essential for autophagy, microtubule associated-protein 1
light chain 3 (MAP1LC3) (reviewed in [37]). After cleav-
age and post-translational modification (lipidation),
MAP1LC3 (LC3-II) associates with autophagosomal
membranes [38], and this modified form of LC3-II is used
as a reliable molecular marker of autophagy [39]. We
transfected RKO cells with vector control (pCEP4) or
pCEP4 expressing ISG20L1. RKO cells ectopically
expressing ISG20L1 showed an increase in LC3-II by
Western analysis (Figure 4a). Next we reverse transfected
RKO cells with control or ISG20L1 siRNA and treated
with etoposide. Etoposide treatment resulted in a consid-
erable increase in both ISG20L1 and LC3-II protein levels
(Figure 4b, right panel). Robust knockdown of ISG20L1
resulted in a significant reduction in LC3-II as measured
by Western (Figure 4b) and an ~70% reduction in LC3
positive cells as measured by immunohistochemistry
(IHC) using an antibody that detects endogenous,
cleaved LC3 (Figure 4c and 4d). To assess if knockdown
of ISG20L1 was modulating autophagy flux, we added
protease inhibitors, E64d and pepstatin A, to inhibit lyso-
somal degradation and LC3-II turnover [39]. RKO cells
were treated with etoposide and lysosomal inhibitors for
8 h, three days after reverse transfection with control or
ISG20L1 siRNA. Under these conditions, knockdown of
ISG20L1 decreased LC3-II levels and thus autophagic
flux (Figure 4e).
To verify these results were not cell type-, damage-, or
assay-specific U2OS cells were transfected with control
siRNA or three unique siRNAs that target ISG20L1 with
varying degrees of knockdown. After treatment with 5-
FU, LC3-II levels decreased in a dose-dependent manner
relative to levels of ISG20L1 knockdown (Figure 5a). We
further determined that knockdown of ISG20L1 in U2OS
cells treated with 5-FU does not alter cell cycle distribu-
tion (Additional File 1).
Autophagy was first studied and quantified using elec-
tron microscopic (EM) detection of autophagosomes [39-
41]. To verify that the modulation of LC3-II observed in
5-FU treated U2OS cells was a reliable marker of
autophagy, we performed EM on parallel cultures of
U2OS cells expressing either control siRNA or the
siISG20L1-1 and representative electron micrographs are
shown (Figure 5b). Morphometric analysis [42,43]
showed an approximately 6-fold decrease in the percent-
age of autophagic vacuole volume fraction after knock-
down of ISG20L1 (Figure 5b, p < 0.0001, n = 25 cells,
duplicate experiments).
As described in the previous section, after autophagy
induction, lipidated LC3-II is associated with autophago-
somal membranes, resulting in the formation of punctate
foci that can be quantified by fluorescence microscopy
[38,39]. To assess autophagy flux in the U2OS cell system,
we used a LC3 (mRFP-GFP-LC3) vector that generates a
LC3 fusion protein tagged at the 5' end with red fluores-
cent protein (RFP) and green fluorescent protein (GFP).
Expression of mRFP-GFP-LC3 allows distinction
between early autophagic organelles (dual RFP+GFP+
puncta) and mature, acidified autolysosomes (RFP+ GFP-
puncta) as the GFP signal is quenched in acidic compart-
ments [39,44]. U2OS cells stably expressing mRFP-GFP-
LC3 were transfected with control or ISG20L1 expressing
vectors and treated with 5-FU for 24 h. Those cells ectop-
ically expressing ISG20L1 had a greater number of total
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(RFP+GFP-) LC3 puncta per cell representing an increase
in maturing autophagosomes (Figure 5c, p < 0.001, n = 50
cells; yellow arrows represent early autophagosomes that
are RFP+GFP+, white arrows indicate late autolysosomal
foci that are RFP+GFP-). These data show that ISG20L1
affects autophagy flux through autophagosome forma-
tion and maturation into autolysosomes.
Figure 3 Knockdown of ISG20L1 does not affect 5-FU-induced apoptotic cell death. (a) RKO colon cancer cells were reverse transfected with 
control (siCon) or ISG20L1 targeting siRNA. Three days after transfection the cells were treated with 5-FU for 48 h and harvested for Western analysis. 
The Western blot (left and middle panel) is representative of three independent experiments and shows no change in caspase-3 or PARP cleavage 
after knockdown of ISG20L1 at either baseline 0 h, where there is low level, basal ISG20L1 expression or after 5-FU treatment. The right panel shows 
DNA laddering as observed on an ethidium bromide-stained gel, a characteristic marker of apoptosis, from the same samples as above treated with 
5-FU. No difference in DNA laddering was evident (lanes are loaded evenly for DNA content). Positive control (+) was obtained from the Roche DNA 
laddering kit and represent U937 cells treated with camptothecin. (b) Flow cytometric analysis was performed on the samples described above at 48 
h after 5-FU treatment and sub-G1 percentage was calculated.
Eby et al. Molecular Cancer 2010, 9:95
http://www.molecular-cancer.com/content/9/1/95
Page 7 of 14
Figure 4 ISG20L1 expression modulates autophagy. (a) RKO cells were transfected with control, pCEP4, or ISG20L1 for 24 h before harvesting for 
Western analysis of ISG20L1, LC3, and actin. The Western blot is representative of four independent experiments. (b) RKO cells were reverse transfected 
with control or siISG20L1 and then treated with etoposide (20 μM) for 8 h before harvesting for Western analysis of ISG20L1, LC3, and actin. Western 
blot is representative of five independent experiments. (c) As performed in (b) knockdown of ISG20L1 suppresses autophagy as measured by IHC us-
ing an antibody specific to the cleaved form of LC3. IHC analysis of LC3 was performed in RKO cells induced to undergo autophagy after treatment 
with etoposide (20 μM). Controls include no siRNA and transfection of siRNA alone. (d) Results from (c) were quantified by counting number of cells 
staining positive for LC3 (dark brown) and dividing by the total number of cells (purple nuclear stain) to attain % LC3. Results are representative of 3 
independent experiments and error bars represent standard deviation. (e) To measure autophagy flux, RKO cells were reverse transfected with control 
or siISG20L1 and treated with etoposide (20 μM) and lysosomal inhibitors (10 μg/mL E64d and pepstatin A) for 8 h before harvesting for Western anal-
ysis of ISG20L1, LC3, and actin. Results are representative of four independent experiments.
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Figure 5 Genotoxic stress-induced autophagy and autophagy flux is modulated by ISG20L1. (a) U2OS cells were reverse transfected with three 
unique siRNAs targeting ISG20L1 and treated for 24 h (0.13 mM 5-FU) to induce autophagy as seen in the siControl lane by the modification of LC3-I 
to LC3-II. Western blot analysis is representative of four independent experiments. (b) U2OS cells were reverse transfected with control or siRNA tar-
geting ISG20L1 and 3 days later treated for 24 h with 5-FU. Electron microscopy was performed and representative images can be seen (left panel) 
Arrowheads indicate autophagosomes or autophagolysosomes. Morphometric analyses was performed on electron micrographs and the percentage 
of autophagic vacuoles per cytoplasmic volume is shown. Results represent the mean and standard error, p < .0001, n = 25 (right panel). This experi-
ment was performed in duplicate. (c) Vector control and ISG20L1 were transfected in U2OS cells stably expressing the tandemly tagged mRFP-GFP-
LC3 (tLC3) and then treated for 24 h with 5-FU. Representative panels show GFP alone and RFP alone for control and ISG20L1 as well as magnification 
of the area outlined by the white box of ISG20L1. White arrows highlight RFP+GFP- only foci representative of autolysosomes (late stage autophagy, 
RFP+GFP-); and yellow arrows indicate early autophagosomes where both GFP and RFP are fluorescing (RFP+GFP+). Quantitation was performed and 
results are the mean and standard error of RFP+GFP- foci expressed as a percentage of total foci (p < .001, n = 50).
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biologically relevant endpoint of cell growth, we analyzed
the effect of ISG20L1 expression using colony formation
assays. We transfected RKO, H1299, HCT116 cells as well
as ATG5+/+ and ATG5-/- mouse embryonic fibroblasts
(MEFs) with control or ISG20L1 expression vectors,
selected the cells in hygromycin for 10 days, and mea-
sured clonogenic growth. ATG5-/- MEFs were derived
from an ATG5-null mouse model system and shown to be
autophagy defective [45].
A representative result from one of the tumor-derived
cell lines (HCT116) is presented in Figure 6a. Cells ectop-
ically expressing ISG20L1 had a 48% reduction in colony
formation as compared to those cultures expressing an
empty vector control. Parallel flow cytometric analyses
were performed at 48, 72, and 96 h after transfection and
no differences were observed in sub-G1 DNA content or
Annexin V staining, between control and ISG20L1
expressing cells (Additional File 2a and 2b). Use of the
ATG5+/+ and ATG5-/- MEFs enabled us to determine if the
decreased clonogenic survival after expression of
ISG20L1 was dependent on ATG5-induced autophagic
processes. As observed in the human cell lines, ectopic
expression of ISG20L1 in the ATG5+/+ MEFs decreased
colony number by ~77% compared to control. Impor-
tantly, this ISG20L1-induced decrease in colony number
was partially rescued in ATG5-/- cells (over 2-fold
increase; Figure 6b). Collectively, these data are consis-
tent with a function for ISG20L1 in genotoxic stress-
induced autophagy and decreased cell survival.
Discussion
Several studies provide evidence for a role of p53 in
autophagy, a process first recognized as important in cell
survival and now thought to function in tumor suppres-
sion [14,46,47]. We strengthen this link between the p53
signaling axis and genotoxic-stress induced autophagy by
identifying ISG20L1 as a transcriptional target of all three
p53 family members. Using a newly generated antibody,
we show that ISG20L1 levels increase in a p53- and
TAp73-dependent manner after various forms of stress.
In addition to p53, the family members p63 and p73 can
bind and directly regulate ISG20L1 expression. Ectopic
expression of ISG20L1 decreased cell survival without
induction of apoptosis as determined by flow cytometric
analyses of sub-G1 DNA content or Annexin V staining,
and the decreased clonogenic survival was partly rescued
in an autophagy deficient background (ATG5-/- MEFs).
ISG20L1 was not involved in modulating 5-FU-mediated
apoptosis, as suppression of ISG20L1 in RKO cells did
not alter the incidence or extent of apoptosis as measured
by PARP and caspase-3 cleavage, sub-G1 content, and
DNA laddering. In contrast, siRNA knockdown of
ISG20L1 decreased genotoxic stress-induced autophagy
as measured by electron microscopy, biochemical, and
immunohistochemical analyses of LC3-II. Thus, we iden-
tified ISG20L1 as a p53-family dependent, genotoxic
stress-induced modulator of autophagy.
The nucleolus is the cellular site of rRNA synthesis and
processing as well as ribosomal assembly [48]. One of the
first connections of p53 to nucleolar signaling was the
observation that a dominant-negative form of the nucleo-
lar protein Bop1 could induce p53-dependent cell cycle
arrest [49]. Recent publications have linked nucleolar
proteins to arbitrating cellular response to stress, includ-
ing autophagy [50-52]. For example, nucleolar ARF can
inhibit the production of the immature 12S rRNA inter-
mediate, interact with the 5.8S rRNA [53], and activate
autophagy in p53-positive cells [54].
Our data validates previous findings of ISG20L1 nucle-
olar localization [36,55]. ISG20L2, a family member of
ISG20L1, also localizes to the nucleolus and is involved in
the processing of 12S rRNA to the mature 5.8S rRNA,
part of the large ribosomal subunit [21]. In vitro assays
have shown that the exonuclease III domain of ISG20L1
is required to degrade single- and double-stranded DNA
and RNA [36,55]. Collectively, the recent findings that
ISG20L1 can degrade RNA, our data and others showing
nucleolar localization of ISG20L1, and our linkage of
ISG20L1 to autophagy suggests it will be important to
examine the role of ISG20L1 in rRNA processing and
ribosomal assembly during cellular response to stress
[36,55,56].
There is growing evidence for the interplay between
autophagy and the p53 family. As mentioned above,
p19ARF and the short mitochondrial form (smARF) are
able to induce autophagy in both p53-dependent and -
independent manners [54]. A number of genes involved
in autophagy are directly regulated by p53 including the
mTOR inhibitors, TSC1 and PTEN, Sestrin1 and
Sestrin2, and the damage-regulated autophagy modulator
(DRAM) [14,46]. Additionally, inhibition of mTOR by
p53 is associated with autophagy and occurs through
DNA damaged-induced signaling involving AMPK and
TSC1/2 [46]. p73 transcriptional activity has also been
linked to autophagy as p73 is bound to a number of genes
involved in metabolism and autophagy [17,18]. Our
results show that ISG20L1 is contributing to cellular
demise by modulating the process of autophagy that is
commonly associated with type II cell death [57,58].
Conclusion
The identification of ISG20L1 as a p53 family target and
discovery that modulation of this target can regulate
autophagic processes further strengthens the connection
between p53 signaling and autophagy. Given the keen
interest in targeting autophagy as an anticancer therapeu-
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Page 10 of 14tic approach in tumor cells that are defective in apoptosis,
investigation of genes and signaling pathways involved in
cell death associated with autophagy is critical.
Methods
Cell Culture and Treatment
The RKO, U2OS, H460, 293FT, HCT116, and H1299 cell
lines were obtained from ATCC and cultured in DMEM
medium with 10% fetal bovine serum supplement and 1%
penicillin-streptomycin. The ATG5+/+ and ATG5-/- MEFs
were a kind gift from Dr. Mizushima (Tokyo Medical and
Dental University) and cultured in DMEM medium with
10% fetal bovine serum [46]. The MDA-MB-231 was also
obtained from ATCC and cultured in McCoy's 5A
medium. The Rh30 cell line was kindly given by Peter
Houghton (St. Jude Children's Research Hospital) and
cultured in RPMI medium with 10% fetal bovine serum.
Normal human epidermal keratinocytes (NHEKs) were
obtained from the Vanderbilt Skin Disease Research Core
and cultured as previously described [59]. Primary
human mammary epithelial cells (HMECs) were purified
from normal breast tissue obtained by the Vanderbilt-
Ingram Cancer Center Human Tissue Acquisition and
Pathology Shared Resource Core, and were isolated and
grown as previously described [22,60].
Figure 6 ISG20L1 decreases cell survival that is partially rescued in ATG5-/- MEFs. (a) HCT116 cells were transfected with pCEP4 vector control 
or ISG20L1, selected in hygromycin B, and the number of colonies formed after selection were counted using BioRad Quantity One software, shown 
in the lower panel. Duplicates of each transfection are shown. Similar results were observed in cultures of RKO and H1299 cells (data not shown). Re-
sults represent the mean and standard error. (b) ATG5+/+ and ATG-/- MEFs were transfected with vector control (pCEP4) and ISG20L1; selected in hy-
gromycin B; and the number of colonies formed after selection were counted using BioRad Quantity One software. Representative pictures are shown 
(upper panels) for each plasmid in both autophagy proficient (ATG5+/+) and deficient (ATG-/-) MEFs. Colony number quantified in the lower panel rep-
resent mean and standard error of each transfection for both ATG5+/+ and ATG-/- MEFs performed in triplicate.
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ment of cell lines mentioned above as described in results
8 Gy 137Cs ionizing radiation, 0.13 mM 5-FU (APP Phar-
maceuticals), 20 μM etoposide (Bedford Laboratories), 5
μg/mL cisplatin (APP Pharmaceuticals), 5 nM paclitaxel
(Sigma), 40 nM rapamycin (Calbiochem). Lysosomal
inhibitors were used at final concentration of 10 μg/mL of
E64d (Calbiochem 330005) and pepstatin A (MP Biomed-
ical 195368).
Cell Transfection and Small Interfering RNA
The following targeting sense strand sequences were used





macon siRNA ISG20L1 pools consisted of the above tar-
geting vectors plus siISG20L1-4
CAGCAGGGCCACUCGUCUA. Dharmacon siRNAs
were reverse transfected into H460, U2OS, and RKO cells
(4.5 × 105) with Lipofectamine2000 (Invitrogen) accord-
ing to the manufacturer's protocol.
To knockdown p53 in NHEK cells, a 19-bp short hair-
pin RNA, corresponding to nucleotides 611 to 629 of p53
RNA (GenBank NM000546), was annealed and cloned
into the self-inactivating lentiviral vector (H1-LV) that
contains a GFP reporter gene under control of human
ubiquitin C promoter for monitoring infection efficiency.
A scrambled oligonucleotide was designed as a negative
control and also cloned in the H1-LV vector. These lenti-
viral vectors were transfected using CaPO4 methods into
293FT cells. After 48 h viral medium was harvested and
with the addition of 8 μg/mL polybrene used to infect
NHEK cells.
293FT cells were transfected using Fugene 6 (Roche) to
make pSico lentivirus. To knockdown p73 in MDA-MB-
231 and Rh30, cells were infected with the pSico lentivi-
rus system that expresses shRNA targeting all isoforms of
p73 as previously described [29]. Forty-eight h later, cells
were treated with rapamycin (40 nM) and RNA harvested
24 h later.
293FT cells were transfected using Lipofectamine2000
with either pCEP4 empty control or cDNAs encoding
p53, TAp63γ, TAp73β, or ΔNp63α and harvested 24 h
later for RT-PCR or Western analysis.
Clonogenic Survival Assays were performed in
HCT116, RKO, H1299 cells, as well as ATG5+/+ and
ATG5-/- MEFs transformed with SV40 large T antigen
obtained from Dr. Mizushima [45]. For all cell lines,
Lipofectamine2000 was used to transfect either pCEP4
empty vector control or ISG20L1 in 60 mm dishes.
Twenty-four h after transfection, cells were selected for
10 days under the appropriate hygromycin B concentra-
tion determined per cell line. Colonies were Wright
stained and analyzed using the Biorad Quantity One soft-
ware.
Western Analysis and Antibodies
Western analyses were performed as previously
described [61]. Fourteen percent SDS-polyacrylamide
gels were used for analysis of LC3 using anti-MAP1LC3-
II (Abgent AP1802a). Additional antibodies used for pro-
tein detection: anti-p53 (Santa Cruz Biotechnology,
PAb1801), anti-β-Actin (Sigma-Aldrich, A5441-0.2 mL),
anti-PARP (Cell Signaling, #9542), anti-Caspase-3 (Cell
Signaling, #9662), anti-p73 (Bethyl A300), p63 (4A4)
(Santa Cruz, sc-8431), and anti-ISG20L1 (Bethyl Labora-
tories, rabbit affinity purified antibody). A peptide for
ISG20L1 antibody production was designed at the C-ter-
minus of ISG20L1, outside of the functional exonuclease
domain found from amino acids 111-275, with the intent
to increase antigenicity and accessibility of the antibody
while decreasing possible cross-reactivity. The peptide
product sequence "HGSRGGAREAQDRRN" targets
amino acids 311-325 of ISG20L1 and these 15 amino
acids are unique to the ISG20L1 sequence.
RNA Isolation and Real-Time Analysis
RNA isolation and all subsequent quantitative real-time
PCR (qRT-PCR) analyses were performed as described
previously [20]. All primer sets were run under the fol-
lowing cycling conditions: 95°C for 3 minutes followed by
40 cycles of: 95°C for 10 sec and annealing at 60°C for 45
sec, with data acquisition during each cycle. Melting
curve analysis following PCR cycling was used to deter-
mine purity and quality of PCR product.
Immunofluorescence, Immunohistochemistry, and 
Electron Microscopy
For immunofluorescence analysis, cells were grown on
glass coverslips and fixed in a 4% paraformaldehyde solu-
tion for 10 min at room temperature. After rinsing with
PBS, the cells were permeabilized with 0.5% Triton X-100
for 10 min. Following another rinse with PBS, cells were
blocked for 15 min at room temperature with 5% BSA-
PBS solution. The ISG20L1 (Bethyl) and FLAG antibod-
ies (Sigma, F3165 anti-FLAG M2) were diluted in 1%
BSA-PBS and incubated on cells at 37°C with 5% CO2 for
1 h. The coverslips were washed 3× with PBS and placed
in 2° rabbit anti-Alexa Flour 546 and mouse anti-Alexa
Flour 488, respectively for 1 h at room temperature, in the
dark. The cells were washed 3× with PBS and counter-
stained with DAPI. All images were obtained using 1000×
magnification on a Zeiss Axioplan microscope equipped
with a Zeiss camera and software.
Direct immunofluorescence was performed on U2OS
cells stably expressing mRFP-GFP-LC3. The mRFP-GFP-
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mori (Osaka University) [44] and Dr. Mizushima (Tokyo
Medical and Dental University) [38]. U2OS stably
expressing the tagged LC3 protein were generated by
transfecting the cells with the mRFP-GFP-LC3 expression
vector using FuGENE 6 (Roche, Indianapolis, IN) and
selecting in geneticin (Cellgro, Manassas, VA). Engi-
neered U2OS cells were then transfected with either
pCEP4 control or ISG20L1 expression plasmids and
treated for 24 h with 5-FU. The cells were fixed and ana-
lyzed as above using a Zeiss Axioplan. Fifty cells were
counted, without knowledge of the plasmids expressed,
and RFP-only foci are reported as a percentage of total
foci.
For immunohistochemistry analysis, cells were grown
on glass coverslips. The cells were fixed, and permeabi-
lized as indicated above for IF analysis. Washes were
done in 1× TBS/0.1% Tween-20 (1× TBST), and cells
were blocked overnight rocking at 4°C in 5% normal goat
serum diluted in TBST. The coverslips were stained spe-
cifically for the cleaved LC3 using the Abgent LC3 spe-
cific 1° antibody (Abgent AP1806a) for 30 min at room
temperature. The coverslips were then washed 3 times in
TBST. The secondary used was the Dako Cytomation
LSAb2 system HRP kit (K0673) according to manufac-
turer's protocol. Cells were analyzed for LC3 staining and
counted at 200× magnification.
U2OS cells were reverse transfected using
Lipofectamine2000 with Dharmacon Nonsilencing con-
trol or siRNA targeting ISG20L1. Three days after reverse
transfection, cells were treated or not for 24 h with 5-FU
to induce autophagy. Cells were harvested, washed with
PBS, and exposed to 2% glutaraldehyde for fixation. Sam-
ple were rinsed in buffer, postfixed in 1% OsO4 for 1 h,
dehydrated through an ethanol series and transferred
into Epon resin. Ultrathin sections (60-70 nm, silver-gray)
were obtained using a Reichert Ultracut E microtome
with a diamond knife, transferred to formvar-coated
grids, and examined on a Phillips CM-10 transmission
electron microscope (FEI, Hillsboro, OR), operating at 80
kV, and images were captured with an AMT 2 mega pixel
camera (Advanced Microscopy Techniques, Danvers,
MA).
Two replicates were performed and each time 25
micrographs were counted blindly for each control and
ISG20L1 knockdown. Additionally, cells were photo-
graphed in an un-biased fashion according to their place-
ment on the grid. Images were quantified using ImageJ
software and taking into account various acceptable
methods [39,42]. We set to scale the pixel ratio to
microns and used measurement analysis to quantify the
area occupied by autophagosome and autolysosomes as
compared to the total cytoplasmic area excluding the
nucleus. Autophagosomes were defined as double or
multiple membrane structures surrounding cytoplasmic
material, and autolysosomes were defined as single mem-
brane structures surrounding cytoplasmic constituents at
various levels of degradation [62].
Flow Cytometric Analyses
Flow cytometry was performed as previously described
using a FACSCaliber instrument (Becton-Dickinson)
[63]. Annexin V-FITC staining detected by flow cytome-
try was performed using the Annexin V-FITC apoptosis
detection kit (BD Pharmingen, 556547).
Chromatin Immunoprecipitation Analyses
HMECs were treated or not with 10 ug/mL cisplatin for
24 h and chromatin was prepared as previously described
[64]. PCR amplification was performed using primers
ISG20L1 forward CAGCCTGTCCAACATGGC and
ISG20L1 reverse GCTGAGGCCATAACTTGGAAA,
GAPDH forward CACCAGCCATCCTGTCCTCC and
GAPDH reverse GTTCCTTCCCAGCCCCCACT, and
p21 forward GCTTGGGCAGCAGGCTG and p21
reverse AGCCCTGTCGCAAGGATC as previously
described [19]. PCR was performed using one cycle of 5
min at 95°C; followed by different number of cycles as
indicated below of: 95° for 30 s, annealing temperature as
indicated below for 45 s, and 30 sec of 72°C; to be finished
with 10 min at 72°C. AEN 40 Cycles Anneal 54°C,
GAPDH 35 Cycles Anneal 62°C, and p21 35 Cycles
Anneal 57°C. Amplified DNA was resolved on a 6% poly-
acrylamide gel and stained after with ethidium bromide.
To attain sufficient levels of p73 for ChIP analysis, ~1.7
× 107rapidly growing Rh30 cells were treated for 24 h
using vehicle control or 40 nM rapamycin. The samples
were prepared and Genpathway analysis performed as
previously described [17] using the p73 antibody (Bethyl
Laboratories, A300) for immunoprecipitation.
DNA Laddering
Cells were counted and 2 × 106 cells were removed and
washed in PBS for DNA laddering analysis. Procedure
was followed according to the Roche Apoptotic DNA-
Ladder Kit (11 835 246 001). In brief, cells were lysed in
an equal volume of proprietary lysis buffer, incubated for
10 min at room temperature, 100 μl of isopropanol was
added and vortexed prior to loading the sample onto filter
tubes. Filter tubes were spun 2× 1 min at 8000 rpm and
washed after each spin with 500 μl washing buffer. After
discarding flow through, filter tube samples were placed
in collection tubes and 100 μl elution buffer was added
and then spun for 1 min at 8000 rpm. DNA obtained
from samples was run on a 1% agarose gel next to 1 kb
DNA ladder and positive control DNA (U937 cells
treated with camptothecin) supplied from Roche.
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Data were analyzed where indicated using the Student's t
test for statistical significance. P values are indicated in
the figure legends and text. Standard deviation and error




TSC2: tuberous sclerosis protein 2; mTOR: mammalian target of rapamycin;
ISG20L1: interferon stimulated gene 20- like 1.
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